Skip to content

Preventing Recurrent 'Idiopathic' Acute Pancreatitis Through Laparoscopic Cholecystectomy (PICUS-2)

Preventing Recurrent 'Idiopathic' Acute Pancreatitis Through Laparoscopic Cholecystectomy (PICUS-2): a Multicenter Randomized Trial

Status
Recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06391359
Acronym
PICUS-2
Enrollment
262
Registered
2024-04-30
Start date
2023-07-30
Completion date
2026-07-30
Last updated
2024-04-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Idiopathic Acute Pancreatitis

Brief summary

Rationale: Annually, acute pancreatitis is diagnosed in 6,500 patients in the Netherlands. In up to 25% of patients no definitive cause can be determined after routine work-up including endoscopic ultrasound and this is deemed to be idiopathic acute pancreatitis (IAP). IAP is known for its high recurrence rate. It is hypothesized that microlithiasis, a type of biliary pancreatitis, is the most common cause of IAP. Laparoscopic cholecystectomy (LC) is highly effective in preventing recurrence of biliary pancreatitis. Currently no randomized trial has compared LC with conservative treatment in patients with IAP after adequate work-up including endoscopic ultrasound. Objective: To assess the effectiveness of LC as compared to conservative treatment in patients after a first episode of 'EUS-negative' IAP. Study design: Multicenter randomized controlled trial. Patients will be followed for one year after randomization. Study population: Adults with a first episode of 'EUS-negative' IAP. Intervention (if applicable): Laparoscopic cholecystectomy versus conservative treatment. Main study parameters/endpoints: The primary endpoint is pancreatitis recurrence. Secondary endpoints include occurrence of biliary events, complications of LC, number and severity of recurrent episodes of pancreatitis, quality of life (QALY), costs (hospital and societal) and cost-effectiveness.

Interventions

PROCEDURELaparoscopic cholecystectomy

Laparoscopic cholecystectomy

Watchful waiting

Sponsors

M.G. Besselink
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

* At least 18 years old * Eligible for early (laparoscopic)\* cholecystectomy * Full required diagnostic work-up of patient has been performed, including EUS * First episode of 'EUS-negative' IAP * Informed consent for participation was obtained \*if required open cholecystectomy is allowed

Exclusion criteria

* Recurrent acute pancreatitis * Diagnosis of chronic pancreatitis * Diagnosis of necrotizing pancreatitis * Current pancreatic malignancy * Prior cholecystectomy * Documented etiology of acute pancreatitis

Design outcomes

Primary

MeasureTime frameDescription
Acute pancreatitis recurrenceWithin 1 year after date of inclusionAcute pancreatitis recurrence, irrespective of etiology

Countries

Netherlands

Contacts

Primary ContactMichiel F.G. Francken, MD
m.f.g.francken@amsterdamumc.nl+31 088-320-7052

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026